PTC THERAPEUTICS, INC. 8-K

What Happened
PTC Therapeutics, Inc. (PTCT) filed an 8-K reporting that it appointed Jessica Chutter to its Board of Directors effective March 24, 2026. Ms. Chutter will serve as a Class I director with a term expiring at the company's 2026 annual meeting. The company also disclosed the cash and equity compensation she will receive under its outside director policies.

Key Details

• Appointment date: March 24, 2026; term expires at 2026 annual meeting.
• Background: Ms. Chutter has over 40 years in healthcare investment banking at Morgan Stanley, including roles as Managing Director (1998–Feb 2026), Vice Chair of Healthcare Investment Banking (2020–Feb 2026), and Chair of Biotechnology Investment Banking (May 2010–Feb 2026). Education: MBA, Harvard Business School; BA Commerce & Honors Economics, McGill University.
• Cash compensation: Outside non-employee director base retainer of $50,000 per year; reimbursement for reasonable travel/meeting expenses.
• Equity compensation (under 2013 LTIP): Initial grant — 3,475 stock options (vest monthly over 36 months beginning one month after grant) and 4,000 restricted stock units (vest in three equal annual installments beginning March 24, 2027). Pro-rated 2026 annual grant — 2,896 stock options (vest in 10 monthly installments starting April 2, 2026) and 3,333 RSUs (1,000 vest June 2, 2026; remaining 2,333 vest Jan 2, 2027). Eligible for standard board equity grants beginning 2027.
• No related-party arrangements or transactions required to be disclosed; press release announcing the appointment was filed March 25, 2026 (Exhibit 99.1).

Why It Matters
This filing updates investors on a board seat change and adds a director with deep biotech investment-banking and capital markets experience—potentially useful for PTC’s strategic, financing, or M&A considerations. Compensation is disclosed and follows the company's standard outside director policy (modest cash retainer plus time-based equity). The appointment fills an open seat and is a governance item investors may weigh when assessing board expertise and oversight.